Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 1;47(7):1075-81.
doi: 10.1016/j.freeradbiomed.2009.07.020. Epub 2009 Jul 18.

Depurinating naphthalene-DNA adducts in mouse skin related to cancer initiation

Affiliations

Depurinating naphthalene-DNA adducts in mouse skin related to cancer initiation

Muhammad Saeed et al. Free Radic Biol Med. .

Abstract

Naphthalene has been shown to be a weak carcinogen in rats. To investigate its mechanism of metabolic activation and cancer initiation, mice were topically treated with naphthalene or one of its metabolites, 1-naphthol, 1,2-dihydrodiolnaphthalene (1,2-DDN), 1,2-dihydroxynaphthalene (1,2-DHN), and 1,2-naphthoquinone (1,2-NQ). After 4 h, the mice were sacrificed, the treated skin was excised, and the depurinating and stable DNA adducts were analyzed. The depurinating adducts were identified and quantified by ultraperformance liquid chromatography/tandem mass spectrometry, whereas the stable adducts were quantified by (32)P-postlabeling. For comparison, the stable adducts formed when a mixture of the four deoxyribonucleoside monophosphates was treated with 1,2-NQ or enzyme-activated naphthalene were also analyzed. The depurinating adducts 1,2-DHN-1-N3Ade and 1,2-DHN-1-N7Gua arise from reaction of 1,2-NQ with DNA. Similarly, the major stable adducts appear to derive from the 1,2-NQ. The depurinating DNA adducts are, in general, the most abundant. Therefore, naphthalene undergoes metabolic activation to the electrophilic ortho-quinone, 1,2-NQ, which reacts with DNA to form depurinating adducts. This is the same mechanism as other weak carcinogens, such as the natural and synthetic estrogens, and benzene.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pathways of naphthalene metabolism.
Fig. 2
Fig. 2
Formation of depurinating adducts in mouse skin treated with naphthalene or one of its metabolites. The values are the average of two determinations that differed by <20%.
Fig. 3
Fig. 3
PAGE analysis of 32P-postlabeled stable DNA adducts obtained from naphthalene and its metabolites in vitro and in vivo. For the in vivo study, naphthalene (1200 or 500 nmol) or its metabolite (500 nmol) was delivered in 50 μl acetone to mouse skin.
Fig. 4
Fig. 4
Quantitative comparison of depurinating and stable adducts formed in mouse skin treated with naphthalene (500 or 1200 nmol) or one of its metabolites (500 nmol). The values are an average of two determinations that differed by <20%.
Fig. 5
Fig. 5
Comparable mechanisms of cancer initiation by natural estrogens and naphthalene.

Similar articles

Cited by

References

    1. IARC. IARC monographs on the evaluation of carcinogenic risks to humans: some traditional herbal medicines, some mycotoxins, naphthalene and styrene. Vol. 82. France, Lyon: 2002. pp. 367–435. - PMC - PubMed
    1. Stanley JS. Environmental Protection Agency, office of toxic substances. Vol. 1. Washington, DC: 1986. Broad scan analysis of the FY82 national human adipose tissue survey specimens, executive summary (EPA-560/5-86-035)
    1. Pellizzari ED, Hartwell TD, Harris BSH, III, Waddell RD, Whitaker DA, Erickson MD. Purgeable organic compounds in mother’s milk. Bull Environ Contam Toxicol. 1982;28:322–328. - PubMed
    1. Environmental Protection Agency. Clean air act amendments of 1990 conference report to accompany S. 1630. Office of Pollution Prevention and Toxics; Washington, DC: 1990. (Report No. 101–952)
    1. Buckpitt A, Boland B, Isbell M, Morin D, Shultz M, Baldwin R, Chan K, Karlsson A, Lin C, Taff A, West J, Fanucchi M, Van Winkle L, Plopper C. Naphthalene-induced respiratory tract toxicity: metabolic mechanisms of toxicity. Drug Metab Rev. 2002;34:791–820. - PubMed

Publication types